Carrera F, Silva J G, Pires C, Oliveira C
Centro Medico Nacional, Lisbon, Portugal.
Nephrol Dial Transplant. 1992;7(9):913-6. doi: 10.1093/ndt/7.9.913.
Non-A Non-B hepatitis (NANBH) is nowadays one of the most common causes of hepatic dysfunction in dialysis patients. We reviewed the records of 231 HBsAg-negative patients in our unit and found 119 patients with biochemical criteria of NANBH (51.5%), 88 of them (68.9%) with circulating antibodies against HCV (chi 2 P less than 0.0001). Such high prevalence of NANBH was due to an outbreak of NANBH in the late 70s and early 80s. Time on haemodialysis (HD) was the major risk factor of NANBH in this population, and no other risk factors were identified. Prevalence of anti-HCV was similar to reports from non-uraemic populations. Anti-HCV seems to be a reliable test to confirm NANBH, but not better than using common biochemical criteria of NANBH to manage these patients in dialysis units.
非甲非乙型肝炎(NANBH)如今是透析患者肝功能障碍最常见的病因之一。我们查阅了本单位231例HBsAg阴性患者的记录,发现119例符合NANBH生化标准(51.5%),其中88例(68.9%)抗HCV抗体呈阳性(χ²检验P值小于0.0001)。NANBH如此高的患病率是由于70年代末和80年代初NANBH的一次暴发。血液透析(HD)时间是该人群中NANBH的主要危险因素,未发现其他危险因素。抗HCV的患病率与非尿毒症人群的报告相似。抗HCV似乎是确诊NANBH的可靠检测方法,但在透析单位管理这些患者时,并不比使用NANBH的常见生化标准更好。